Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Webcasts|August 23, 2024
Beyond Jet Milling: A Deep Dive into Carrier-Based Formulation and Process Optimization
Author(s)Lonza
Webinar Date/Time: Fri, Sep 13, 2024 10:00 AM EDT
Discover the essentials of carrier-based formulations for dry powder inhalers. Learn about jet milling, high shear and low shear mixing techniques, focusing on performance and stability.
Register Free:
Carrier-based formulations for dry powder inhalers are carefully designed to transport extremely small particles into the lungs. Jet milling can be used to micronize these particles, with both high and low shear mixing processes used to formulate mixtures capable of carrying the fine API particles into the deep lung. This webinar will look at the requirements for pulmonary delivery via carrier-based inhaled powder formulations, and how jet milling can be used to manufacture effective and stable materials for these formulations. It will also look at how it can be integrated into the overall formulation development process.
Key Learning Objectives:
- Explore the advantages of an integrated approach for carrier-based formulation development
- Discover best practices for screening and scaling up jet milling for high-quality outcomes
- Find out how a QbD approach can ensure a smooth and efficient development and scale-up journey
Who Should Attend:
- Pharmaceutical industry directors
- Principal Investigators/CMC Leads
- Manufacturing and development engineers and scientists
Speakers:
Beatriz Noriega Fernandes
Principal Investigator, Manager CMC, Respiratory Delivery
Lonza
Beatriz Noriega Fernandes is a Principal Investigator at Lonza Bend, Oregon. She leads a portfolio of programs and identifies potential strategies for dry powder inhalation delivery. She is a Biological Engineer by training, with a PhD in Pharmaceutical Technology from the University of Lisbon, Portugal. Her background includes more than eight years of experience in various areas of dry powder inhaler development, including the formulation and manufacture of inhalable clinical products.
Ilaria Valente
Technical Sales Manager
Lonza
Ilaria Valente is a technical sales manager at Lonza. She holds a Bachelor’s degree in Foreign Languages for Communication and Business from the Catholic University of Milan. With a decade of experience, she started her career in sales, progressed through account management and business development roles, and then moved to the drug substance technical sales team. In her role, she is responsible for the evaluation of requests and supporting the sales organization in writing micronization and integrated services proposals, and for coordinating the technical team during the evaluation process.
Register Free:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.